Bristol Myers Squibb Boosts AI Power with Nvidia Supercomputer

Bristol Myers Squibb has announced its acquisition of a next-generation computing system from chip manufacturer Nvidia to bolster its artificial intelligence efforts in drug discovery and development.

The company will be the first in the life sciences sector to adopt Nvidia's DGX SuperPOD, featuring the new Vera Rubin systems. This investment significantly expands the company's AI computing capacity.

This move is part of a growing trend among pharmaceutical firms to invest in AI infrastructure to expedite the identification of drug targets and improve the success rates of experimental drugs in clinical trials.

Bristol Myers indicated that the new capabilities will enable the processing of many more potential drug candidates at the early stages of development, a substantial increase from previous capacities. Furthermore, the company is already leveraging AI tools to reduce the time required for preparing medicines for trials by 20% to 30%.

This advanced AI system is also noted for its energy efficiency, offering substantially more compute power per watt consumed, a crucial factor given rising electricity costs. The investment addresses the rapidly increasing computing demands as Bristol Myers deploys larger AI models across its research operations, impacting both small-molecule and large-molecule programs.

One experimental treatment for sickle cell disease currently in early clinical development at Bristol Myers likely owes its discovery to AI-enabled research, underscoring the transformative potential of this technology.